1
20091243 1 2 3 1. 2. 3. 4. 2
1. 1-1 1-2 2. 2-1 2-1-1 2-1-2 2-1-3 2-1-4 2-1-5 2-2 2-2-1 2-2-2 2-2-3 2-2-4 2-2-5 3
2. 2-3 2-3-1 2-3-2 2-3-3 2-3-4 2-3-5 2-4 2-4-1 2-4-2 2-4-3 2-4-4 2-4-5 3. 3-1 3-2 4
1. 5
1. 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 3-2 6
1. 392 64 B 135 65 58 26 42 7
1. 392 20042005992006 70392299 1259 8
1. 20839 2004 20062001 9
1. 39220 120A B A 2007200814 B20089 J 10 92
1. 39220 11
1. 392 20032005 200621200730 2005 2004 12
1. 20840 3 80 13
1. 20841 14
1. A 42 GM1 15
1. 70 2005 2006 AB B 2008 16
1. 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 17
1. 20084 32 18
1. 4 70 19
20 1.
21 1.
22 1.
23 1.
24 1.
25 1.
26 1.
27 1.
1. 28
1. 29
30 1.
31 1.
1. 4 32
1. 33
1. 34
1. 35
1. 36
1. 37
1. 2003 20072008 B 2005 2005 2004 38
1. 39
1. 40
1. 1 41
1. 42
1. 43
1. 1612612 745148161 41552104 873103182 664124167 231927 903014 762219 44
1. C- C C+ B- B B+ A- A A+ 45
1. C- C C+ B- B B+ A- A A+ 46
1. C- C C+ B- B B+ A- A A+ 47
1. C- C C+ B- B B+ A- A A+ 48
1. C- C C+ B- B B+ A- A A+ 49
1. C- C C+ B- B B+ A- A A+ 50
1. C- C C+ B- B B+ A- A A+ 51
2. 52
2-1 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 53
2-1 54
2-1 55
56 2-1
57 2-1
58 IPC 28,8702002 2-1
59 2-1
2-1 20026,00020052006 3,000 60
2-1 61
2-1 62
2-1 2002 1,0002006 63
2-1 64
2-1 20 65
2-1 PFIZER 66
2-1 30~40 67
2-1 NOVARTIS 103 68
2-1 3 2006 7020022004 20022006 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 69
2-1 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 70
2-1 6,000 NOVARTIS MG 71
2-1 72
2-1 73
2-1 74
2-1 75
2-1 76
77 2-1
2-1 3 78
2-1 79
2-1 80
2-1 81
2-1 3 82
2-1 83
2-1 84
2-1 5 85
86 2-1
87 2-1
2-1 5 88
2-1 89
2-1 F* *F 90
2-1 F 91
2-1 F 92
2-1 F 93
2-1 94
2-1 F20022005 95
2-1 F* *F 96
2-1 F 97
2-1 PCR F 98
2-1 99
2-1 F20022005 100
2-2 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 101
2-2 102
2-2 ESiPS 103
2-2 104
2-2 IPC 7,9862000 105
2-2 20021,000 106
2-2 30 107
2-2 108
2-2 20012002600 109
2-2 60% 110
2-2 20 CURAGEN AMGENPFIZERCHIRON 111
2-2 112
2-2 90 113
2-2 3 3 3 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 114
2-2 1,000 3 90 2 115
2-2 116
2-2 117
118 2-2
2-2 119
2-2 120
2-2 121
2-2 122
123 2-2
2-2 3 124
2-2 125
2-2 F* 10 *F 126
2-2 F 127
2-2 F 128
2-2 129
2-2 130
2-2 F20022005 131
2-3 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 132
2-3 133
2-3 DDS DDS 134
135 *1: *2: *3: 2-3
2-3 IPC 29,3722000 136
2-3 20002003 137
2-3 GE MEDICAL SYSTEMS PHILIPS ELECTRONICS 138
2-3 139
2-3 PET 140
2-3 X CT3 MRI PET 141
2-3 BOSTON SCIENTIFIC MEDTRONIC 142
2-3 DDSCORDISBECTON DICKINSON DDS 143
2-3 2004 GE MEDICAL SYSTEMS 144
2-3 XCT MRIGE MEDICAL SYSTEMS PHILIPS ELECTRONICS XCT MRI 145
2-3 1020 PETPHILIPS ELECTRONICSGENERAL ELECTRIC PET 146
2-3 147
2-3 148
2-3 XCT PET 149
2-3 PET4 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 150
2-3 3,000-4,000 XCTMRIGE MEDICAL SYSTEMSPHILIPS ELECTRINICS PET 20002006PET 2003 BOSTON SCIENTIFIC MEDTRONIC XCTMRI XCT 151
2-3 152
2-3 153
154 160 2-3
2-3 7 155
2-3 XCTMRI6 XCT2005141880 80.6 7 156
2-3 157
2-3 2 158
2-3 XCT21 159
160 2-3
161 XCT CT34 CT XCT 2-3
2-3 XMRI XCT http://www.nirs.go.jp/news/press/2006/04_19_01.shtml 200510 XCT 19 XCT 162
2-3 163
2-3 XCTF* 20 XCT *F 164
2-3 X2 F 165
2-3 XCTF4C093CA23 FX F 166
2-3 X XX F 167
2-3 F 168
2-3 X F 169
2-3 170
2-3 171
2-3 XCT X X X F20022005 172
2-3 F* 20 *F 173
2-3 F 174
2-3 S/N F 175
2-3 F 176
2-3 F 177
2-3 178
2-3 179
2-3 F20022005 F 180
2-4 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 181
2-4 182
2-4 2 183
184 2-4
185 2-4
186 IPC16,321 2000 *1: *2: *3: 2-4
187 *1: *2: *3: 2-4
188 2-4
2-4 20002002 3000 2000 1000 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 1149 1054 1022 816 628 335 31 17 10 218 358 467 205 122 60 45 38 3 792 847 932 1457 1588 1761 1387 571 139 2159 2259 2421 2478 2338 2156 1463 626 152 189
190 GENENTECH PFIZER 2-4
2-4 191
2-4 2003-2004 2006 192
2-4 2 193
194 26 20 27 HOPKINSJOHNSUNIVERSITY 19 27 MERCK 18 28 17 30 AMGEN 16 31 GLAXOSMITHKLINE 15 34 MILLENNIUMPHARMACEUTICALS 14 38 NOVARTIS 13 38 12 38 11 40 F.HOFFMANN-LAROCHE 10 40 9 42 WYETH 8 45 GLAXOSMITHKLINEBIOLOGICALS 7 47 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 6 53 CHIRON 5 56 4 80 PFIZER 3 95 2 158 GENENTECH 1 26 20 27 HOPKINSJOHNSUNIVERSITY 19 27 MERCK 18 28 17 30 AMGEN 16 31 GLAXOSMITHKLINE 15 34 MILLENNIUMPHARMACEUTICALS 14 38 NOVARTIS 13 38 12 38 11 40 F.HOFFMANN-LAROCHE 10 40 9 42 WYETH 8 45 GLAXOSMITHKLINEBIOLOGICALS 7 47 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 6 53 CHIRON 5 56 4 80 PFIZER 3 95 2 158 GENENTECH 1 16 20 16 19 16 18 16 17 17 16 18 15 19 14 19 13 20 DIVERSA 12 20 11 20 BASFAKTIENGESELLSCHAFT 10 23 9 24 MONSANTOTECHNOLOGY 8 25 SYNGENTAPARTICIPATIONS 7 26 SYNGENTA 6 28 5 65 4 92 3 101 2 111 1 16 20 16 19 16 18 16 17 17 16 18 15 19 14 19 13 20 DIVERSA 12 20 11 20 BASFAKTIENGESELLSCHAFT 10 23 9 24 MONSANTOTECHNOLOGY 8 25 SYNGENTAPARTICIPATIONS 7 26 SYNGENTA 6 28 5 65 4 92 3 101 2 111 1 20 2-4
195 13 BIOGENIDEC 20 13 19 13 18 14 17 15 AMGEN 16 16 WYETH 15 16 SCHERING-PLOUGH 14 18 CURAGEN 13 19 DIVERSA 12 21 11 22 10 24 PFIZER 9 24 8 26 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 7 26 CHIRON 6 28 5 30 4 35 3 42 GENENTECH 2 68 EXELIXIS 1 13 BIOGENIDEC 20 13 19 13 18 14 17 15 AMGEN 16 16 WYETH 15 16 SCHERING-PLOUGH 14 18 CURAGEN 13 19 DIVERSA 12 21 11 22 10 24 PFIZER 9 24 8 26 THEREGENTSOFTHEUNIVERSITYOFCALIFORNIA 7 26 CHIRON 6 28 5 30 4 35 3 42 GENENTECH 2 68 EXELIXIS 1 20 20 21 19 21 18 21 17 21 16 22 15 22 14 23 13 25 12 25 11 25 10 26 9 28 8 44 7 44 6 45 5 50 4 54 3 71 2 101 1 20 20 21 19 21 18 21 17 21 16 22 15 22 14 23 13 25 12 25 11 25 10 26 9 28 8 44 7 44 6 45 5 50 4 54 3 71 2 101 1 43 20 44 19 45 18 47 17 48 16 49 15 53 14 53 13 55 12 56 11 57 10 61 9 73 8 88 7 90 6 100 5 105 4 105 3 117 2 158 1 43 20 44 19 45 18 47 17 48 16 49 15 53 14 53 13 55 12 56 11 57 10 61 9 73 8 88 7 90 6 100 5 105 4 105 3 117 2 158 1 20 2-4
2-4 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 196
2-4 197
2-4 3<20;20-50;>50; /3(30%;30-59%;60%) /315;15-49;50 198
2-4 400-500 GENENTECHPFIZER 20002006 GENENTECHPFIZER 102 199
2-4 200
2-4 201
202 2-4
2-4 115 203
2-4 3 2005-151972 74.2 11 204
2-4 205
2-4 206
2-4 207
2-4 208
2-4 209
2-4 41 3 210
2-4 211
2-4 F* 10 *F 212
2-4 F cdna F 213
2-4 4C063QA01 DNAcDNAPCR 4B063QA18PCR F 214
2-4 215
2-4 216
2-4 F20002005 217
2-4 F* 20 *F 218
2-4 4D006PA01 4D038AA08 F 219
2-4 4D028AA08 3 F 220
2-4 221
2-4 222
2-4 F20002005 223
3. 224
3. 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 3-2 225
3. 226
3. 1. 1-1 1-2 2. 2-1 2-2 2-3 2-4 3. 3-1 3-2 227
3. 201068,9294,000 20103,597500 4-5 7 228
229 CSF Colony Stimulating Factor 3.
230 QOL 3.
3. PFIZERNOVARTIS 5 64.569.5 231
3. DNADNA 2007 45 Biogen idecgenentech 232
233 3.
3. PFIZER 5 234
3. PFIZER PFIZER PFIZER S VREMRSA 200812 PFIZER FDA2007/8HIV HIV 235
3. 2015 20154,900 236
3. PFIZER ASTRAZENECAMERCK 4 237
3. 3,000 20076 238
3. SHPS-1 239
Contact Information http://www.ipb.co.jp/ 240